Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects
| Autor: | W. Bossart, R Luethy, K Moelling, R Cone, Rainer Weber |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Microbiology (medical)
Adult Male Lymphocyte HIV Infections Asymptomatic Severity of Illness Index Virus DNA vaccination HIV Envelope Protein gp160 HIV Seropositivity Medicine Humans Immunization Schedule AIDS Vaccines biology business.industry Patient Selection Vaccination virus diseases General Medicine biology.organism_classification Virology Infectious Diseases medicine.anatomical_structure Treatment Outcome Lentivirus Immunology biology.protein HIV-1 Female Viral disease Antibody medicine.symptom business Follow-Up Studies |
| Zdroj: | European journal of clinical microbiologyinfectious diseases : official publication of the European Society of Clinical Microbiology. 20(11) |
| ISSN: | 0934-9723 |
| Popis: | The aim of the study was to investigate the safety of an HIV-1 gp160 plasmid vaccine. Four asymptomatic HIV-1-infected subjects with CD4+ lymphocyte counts >500/microl were injected with four times 400 microg of HIV-1 modified gp160 env and rev coding DNA vaccine at 0, 4, 10 and 28 weeks. Safety parameters, including autoimmune antibodies as well as CD4+/CD8+ cell counts and HIV-1 plasma concentrations, were monitored for 52 weeks after the first vaccine application. Follow-up data for more than 3 years are now available. The DNA vaccine proved to be safe and, specifically, did not induce anti-DNA autoimmune antibodies. Vaccination had no long-term effects on the CD4+/CD8+ lymphocyte counts, plasma HIV-1 RNA concentrations or disease progression. The present data supplement published data from Philadelphia, USA, where a dose-escalating study (30-300 microg) with the same HIV-1 DNA vaccine was performed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink